Eli Lilly's stock has surged 53% over the past twelve months, driven by a 47% revenue jump and a 47% operating margin that far outpace the broader market. Its cardiometabolic franchise delivered a combined $12.8 billion in global revenue in the first quarter of 2026, powered by strong demand for its diabetes and obesity treatments. Despite this momentum, the stock trades at a price-to-earnings multiple of 41.6, a steep premium to the S&P 500 median of 24.3, raising questions about whether the current price already captures future success. Management has raised full-year revenue guidance by $2 billion to a range of $82 billion to $85 billion, but warns that pricing headwinds in the low to mid-teens could persist. The key test for investors is whether volume growth can overcome these pricing pressures and sustain the rally.
Eli Lilly and CompanyStrong demand for diabetes and obesity treatments drove 47% revenue jump and raised guidance.
AbbVie Inc
Amgen Inc
Johnson & Johnson
Merck & Company Inc